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Introduction JPET 232553 6 metabolites: 19-and 20-hydroxyeicosatetraenoic acid ethanolamides (HETE-EAs) and the 5, 8, 11, and 14, (Alberich Jorda et al., 2004; Pratt-Hyatt et al., 2010; Snider et al., 2007; Snider et al., 2009; Snider et al., 2008; Sridar et al., 2011; Stark et al., 2008) . CYP2J2 is a CYP450 epoxygenase that is mainly expressed in the cardiovascular system (Wu et al., 1996) , but it is also expressed in the intestines, stomach and other tissues (Paine et al., 2006; Wu et al., 1996; Zeldin et al., 1997b) ; (Enayetallah et al., 2004) . CYP2J2 has been shown to play an important role in the intestinal metabolism of two antihistamines (ebastine and astemizole), but its ability to metabolize AEA in the intestine
has not yet been investigated (Hashizume et al., 2002; Matsumoto et al., 2002) . This manuscript provides information on the metabolism of AEA by purified human CYP2J2 in the reconstituted system and by human intestinal microsomes.
JPET 232553 8 using a desktop centrifuge for 5 min. The organic layers were collected and dried down under a constant stream of nitrogen gas. The dried samples were resuspended in 100 μ L of methanol and 10 μ L aliquots were subjected to electrospray ionization-liquid chromatography/mass spectrometry (ESI-LC/MS) analysis. The standard curves for the various metabolites that were used for the quantification and determination of the K M and k cat values were generated by subjecting various known amounts of authentic standards to the same sample workup and ESI-LC/MS analysis.
ESI-LC/MS Analysis.
Samples (10 μ L) were injected onto a Hypersil ODS column (5 μ m, 4.6 × JPET 232553
Results

AEA Metabolism by Human Intestinal Microsomes.
To investigate the ability of human intestinal microsomes (HIM) to metabolize AEA, incubations containing 200 µg of HIM were used to metabolize AEA for 30 min at 37°C as described in Materials and Methods. Figure 1 (Top) shows the extracted ion chromatogram at m/z 364 for the mono-oxygenated metabolites from this reaction with peaks eluting at 15.9, 18.4, 19.2, 19.8, 14, 11, 8, and 5, 6 -EET-EAs, respectively. Although no standard is commercially available for positive identification of the product eluting at 17.3 min, it is thought to be 19-HETE-EA (Pratt-Hyatt et al., 2010; Snider et al., 2007; Snider et al., 2009 ). The peaks eluting at 11.6, 13.4, and 15.6 min observed at m/z 382 correspond to the diols formed when the epoxides (m/z 364) are hydrolyzed (Figure 1 , Bottom). Figure 2 shows the kinetic curves for the products formed by human intestine microsomal metabolism of AEA. Two different kinetic models were utilized to determine the K m and V max values for the formation of 20-HETE-EA, 5,6-, 8,9-, and 11,12-EET-EAs. Michaelis-Menten kinetics was used to determine the formation rate of 20-HETE-EA. The presence of sEH altered the formation of all four EET-EAs. As a result, double reciprocal plots were used to estimate the kinetic constants for three of the EET-EAs. Metabolism of Anandamide by Human Recombinant CYP2J2. Several P450s are known to be expressed in the intestine including CYP3A4, CYP2C9, CYP2C19, and CYP2J2 (Paine et al., 2006) . Although the expression levels of CYP2J2 in the intestine are reported to be less than 2% of the total P450, the physiological relevance of 2J2 in the intestine has previously been suggested by reports of its contribution to the intestinal metabolism of certain drugs such as ebastine and astemizole (Hashizume et al., 2002; Matsumoto et al., 2002) . Arachidonic acid (AA) is metabolized by recombinant CYP2J2 to form four regioisomeric EETs (Wu et al., 1996) .
As shown in Figure 3 , due to the similarities between the structures of AEA and AA, and the fact that AEA is a substrate for several other CYP450s including CYP2D6, CYP3A4, and CYP2B6 (Omura and Sato, 1964; Snider et al., 2007; Snider et al., 2008; Sridar et al., 2011) , we investigated the possibility that anandamide could also be a substrate for CYP2J2. (Proctor et al., 1987) . Since it is known that CYP2J2 catalyzes the metabolism of AA in the intestine (Delozier et al., 2007) and that AA is a relatively potent inhibitor of several P450s, , 5, 8, 11, and 14, 43, 35, 38, and 36%, respectively (Figure 6 ). the major product of P450-catalyzed AEA metabolism by HLM and HIM (Snider et al., 2007) . In relation to the epoxides, the 8,9-EET-EA was the preferred product formed by HLM, but the 11,12-EET-EA seems to be the preferred product formed by HIM based on the V max and the catalytic efficiency (V max /K m ).
Contribution of Individual
To date, the CYP450s known to metabolize AEA are reported to be found primarily in the liver, kidney, and brain (Snider et al., 2007; Snider et al., 2008; Sridar et al., 2011) . CYP2J2 is the most abundantly expressed CYP450 in the cardiovascular system (Wu et al., 1996) , but it is also expressed in other tissues such as the intestines (Paine et al., 2006; Wu et al., 1996; Zeldin et al., 1997b) , lung (Zeldin et al., 1996) , pancreas (Zeldin et al., 1997a) , kidney (Ma et al., 1999) , liver (Nishimura et al., 2003; Wu et al., 1996 ), brain (Dutheil et al., 2009 ), and stomach (Enayetallah et al., 2004 . CYP2J2 has been reported to participate in the intestinal metabolism of the nonsedating antihistamines ebastine and astemizole (Hashizume et al., 2002; Matsumoto et al., 2002 ). CYP2J2 metabolizes AA, which is structurally similar to AEA, to give four EETs which have a plethora of biological actions in the body including in the intestine (Proctor et al., 1987) .
Incidentally, Bystrom and colleagues reported that defective CYP2J2 metabolism of AA to 11,12-EET, which promotes bacterial pathogenesis, may be responsible for regulating bacterial clearance in Crohn's disease (Bystrom et al., 2013) . We have shown here that CYP2J2
This article has not been copyedited and formatted. The final version may differ from this version. , 2002; Wu et al., 1996) . Although CYP2J2 is known for its racemic production of the four epoxides (1:1:1:1) from AA (Wu et al., 1996) , the four EET-EAs are produced in a ratio of 2:1:1:2 for the 5,6-:8,9-:11,12-:14,15-EET-EA.
The kinetic constants, K M and k cat , were determined for each of the five major metabolites , 2010; Snider et al., 2008; Sridar et al., 2011) . However, in the presence of 50 µM AEA, the total turnover rate for the formation of all the products by recombinant CYP2J2 was calculated to be about 7 nmol of total product formed/nmol of CYP2J2/min. For comparison, in the presence of 100 µM AA, two separate labs have determined that the turnover for AA was 0.065 and 0.165 nmol of total product formed/nmol of CYP2J2/min (King et al., 2002; Wu et al., 1996) . This is a difference of more than 40 fold. In agreement with the studies by McDougle et al. (2014) , this suggests that AEA may be a much better substrate for CYP2J2 in vivo than AA.
This article has not been copyedited and formatted. The final version may differ from this version. The pharmacological relevance of CYP2J2 activity in the intestine has previously been suggested by reports of its contribution to the intestinal metabolism of certain drugs (Hashizume et al., 2002; Matsumoto et al., 2002) . Although CYP2J2 is present in the intestine, it does not appear to be a significant contributor to AEA metabolism in the intestine in comparison with other P450s.
In fact, when CYP2J2 was inhibited, more of the 8,9-and 11,12-EET-EA products were produced. This may be due to compensation from other, more efficient CYP450s for the loss of CYP2J2 activity (Kaspera et al., 2014) . On the other hand, CYP3A4 and CYP2C9 are responsible for the formation of about 50% of the 20-HETE-EA and 11,12-EET-EA produced in the intestine, respectively. Other P450s such as CYP2C19 and CYP2D6, both of which are known to be expressed at appreciable levels in the intestine, probably contribute significantly to AEA metabolism in the intestine as well (Paine et al., 2006; Snider et al., 2008) . Since the intestinal absorption of AA was reported to be in the µM-mM range (Chow and Hollander, 1978) , under physiological conditions, CYP2J2-catalyzed activity will probably be inhibited by roughly 30% due to the presence of AA in the intestine.
Previous studies from our lab have suggested a physiological importance for the 5,6-EET-EA metabolite of AEA since it exhibits nanomolar affinity for the CB2 receptor and it decreases intracellular cAMP accumulation in Chinese hamster ovary cells expressing the CB2 receptor (Snider et al., 2009 ). Moreover, this metabolite is more biologically stable than the parent AEA with an estimated half-life of 32 min (Snider et al., 2009 ). This half-life is also four times longer than the half-life reported for the structurally similar 5,6-EET metabolite formed by the metabolism of AA (Fulton et al., 1998) . Since the 5,6-EET-EA is one of the AEA metabolites formed in the intestine and its presence can be quantified in the presence of sEH unlike 14,15-This article has not been copyedited and formatted. The final version may differ from this version. EET-EA, which is formed at very low levels, it may play an important anti-inflammatory role in the intestine.
Intestinal motility is usually attributed to CB1 receptor activation; however, in an inflammatory state, the CB2 receptor may predominate (Mathison et al., 2004) . The reactions were initiated with 1 mM of NADPH and allowed to continue for 30 min at 37°C.
The reactions were quenched and products isolated and analyzed as described in Materials and
Methods. Each bar represents the average amount of product formed ± SEM. Statistical significance was determined by the student's t test, *, P < 0.05. 
